{"id":"NCT03461146","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan","officialTitle":"A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-05","primaryCompletion":"2018-12-03","completion":"2018-12-17","firstPosted":"2018-03-09","resultsPosted":"2021-05-07","lastUpdate":"2023-12-29"},"enrollment":24,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Anemia; Hemodialysis Dependent Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"MT-6548","otherNames":["vadadustat","AKB-6548"]}],"arms":[{"label":"MT-6548","type":"EXPERIMENTAL"}],"summary":"For hemodialysis subjects not receiving ESAs with anemia associated with chronic kidney disease, evaluate Hb correction and maintenance effect and safety of MT-6548.","primaryOutcome":{"measure":"Mean Hb Level of Week 20 and Week 24","timeFrame":"Up to Week 24","effectByArm":[{"arm":"MT-6548","deltaMin":10.75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":["34115437"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":24},"commonTop":["Nasopharyngitis","Shunt stenosis","Diarrhoea","Skin abrasion","Vomiting"]}}